Eli Lilly and Company

Science has been our calling from the beginning. Colonel Eli Lilly founded the company in 1876 and charged employees to “take what you find here and make it better and better.” More than 147 years later, we remain committed to his vision through every aspect of our business and the people we serve, starting with discovering the best treatments for those who take our medicines and extending to health care professionals, employees and the communities in which we live. Moreover, you can also count on the team at Lilly to be incredibly civic-minded, supporting our communities through philanthropy, volunteerism, and a creative and innovative can-do spirit.

When you’re on a mission to do what’s never been done before, you seek people willing to challenge the status quo of medicine. Those willing to relentlessly pursue what’s next, all in the name of health above all. #WeAreLilly

893 S Delaware St
Indianapolis, IN 46285

Discovery is
in our DNA

Exceptional people with an
extraordinary purpose.
Our values and commitment
have guided our success
for over 140 years.

Explore Careers

We are Lilly

Why do our employees love coming to work each and every day? Here’s what they have to say.

“Opportunity for growth is actually the biggest reason that I ended up hiring into Lilly.”

Kavita - Associate Director, Packaging Operations
“Lilly worked bery hard to be able to allow me to settle into my role, but they also had a great deal of consideration for my life outside of work.”

Adrian - Associate Director, IDM
“What we do matters, it matters to the people that we interact with. It matters to people in our families and it matters to people around the world.”

Cecile - Sr Director, Design Hub Foundations

39,000 global employees coming together from diverse backgrounds to create medicines that make life better for people around the world. Get to know us through our Powered by Purpose series.

View Stories

NEWS

A Novo Nordisk flag flies in the wind/Courtesy jor

Strategy Behind Lowered Insulin Prices: Novo Nordisk and Eli Lilly

After Eli Lilly announced it would take measures to cap insulin prices, Novo Nordisk will reportedly follow suit. There may be strategic reasoning behind these moves.

March 15, 2023

2 min read

Jia Jie Chen

Drug Development

Lilly’s Alzheimer’s Struggles Continue as Preclinical Disease Asset Fails Phase III

Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease.

March 9, 2023

2 min read

Tristan Manalac

Business

Lilly Bets $630M on Pain Target Novartis Failed

Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.

March 2, 2023

2 min read

Kate Goodwin

Drug Development

Lilly, Nektar Stumble in Phase II Lupus Trial

Rezpegaldesleukin, Lilly’s and Nektar Therapeutics’ candidate for systemic lupus erythematosus, fell short of its primary efficacy endpoint in the Phase II ISLAND trial.

February 24, 2023

2 min read

Tristan Manalac

Drug Development

FDA Approves First Reversible BTK Inhibitor

The FDA granted Eli Lilly’s Jaypirca accelerated approval for the treatment of adults with relapsed or refractory mantle cell lymphoma.

January 30, 2023

2 min read

Tristan Manalac

Elderly woman sitting alone and looking sadly outside the window

FDA

Recent Regulatory Decisions Highlight Evolution of the Anti-Amyloid Theory

The FDA’s approval of Biogen and Eisai’s Leqembi and subsequent decision not to approve Eli Lilly’s donanemab have sparked debate anew about the anti-amyloid theory in Alzheimer’s.

January 25, 2023

3 min read

Heather McKenzie

An old man looking at camera, covering his mouth with his hand. Black and white photo.

Drug Development

FDA Made the Right Call on Lilly’s Donanemab, Some Experts Say

Research hasn’t shown that removing amyloid plaques alone improves function in Alzheimer’s patients, said Sharon L. Rogers, CEO of AmyriAD.

January 24, 2023

4 min read

Lisa Munger

Drug Development

Innovative Trial Design may have Cost Lilly’s Donanemab Accelerated Approval

The FDA issued a complete response letter Thursday refusing accelerated approval for Eli Lilly’s Alzheimer’s disease candidate donanemab.

January 20, 2023

2 min read

Tristan Manalac

Drug Development

Lilly Gears Up for ‘Unprecedented Year,’ Touts Promising Pipeline

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.

January 11, 2023

2 min read

Tristan Manalac

JOBS